| 14.65 0 (0%) | 01-16 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 19.36 | 1-year : | 22.61 |
| Resists | First : | 16.57 | Second : | 19.36 |
| Pivot price | 14.58 |
|||
| Supports | First : | 13.9 | Second : | 12.25 |
| MAs | MA(5) : | 14.96  |
MA(20) : | 14.5 |
| MA(100) : | 16.71 |
MA(250) : | 14.59 |
|
| MACD | MACD : | 0 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 46.9 |
D(3) : | 49.1 |
| RSI | RSI(14): 49.7 | |||
| 52-week | High : | 30.1 | Low : | 9.76 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ CLPT ] has closed below upper band by 47.6%. Bollinger Bands are 60.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 30 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 15.1 - 15.18 | 15.18 - 15.24 |
| Low: | 14.13 - 14.21 | 14.21 - 14.28 |
| Close: | 14.53 - 14.65 | 14.65 - 14.77 |
ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under direct, and intra-procedural magnetic resonance imaging (MRI) guidance. It offers ClearPoint system for the insertion of deep brain stimulation electrodes and biopsy needles, and the infusion of pharmaceuticals and laser catheters into the brain; and ClearPoint Neuro Navigation System, an MRI suite. It has license and collaboration agreements with Boston Scientific Corporation, The Johns Hopkins University, Clinical Laserthermia Systems Americas Inc, Koninklijke Philips N.V., Blackrock Neurotech, and University of California and San Francisco. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.
Thu, 15 Jan 2026
Precision Trading with Clearpoint Neuro, Inc. (CLPT) Risk Zones - Stock Traders Daily
Mon, 12 Jan 2026
ClearPoint Neuro (CLPT) Reports Strong Preliminary Revenue Growt - GuruFocus
Mon, 12 Jan 2026
ClearPoint Neuro Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Revenue - ACCESS Newswire
Mon, 05 Jan 2026
ClearPoint Neuro Signs Consent to Note Purchase Agreement With Oberland Capital - TradingView — Track All Markets
Wed, 24 Dec 2025
What Creates a Long-Term Growth Opportunity for ClearPoint Neuro (CLPT)? - Yahoo Finance
Wed, 12 Nov 2025
ClearPoint Neuro: CRO Facility Should Reaccelerate Growth (NASDAQ:CLPT) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 30 (M) |
| Shares Float | 26 (M) |
| Held by Insiders | 7.8 (%) |
| Held by Institutions | 39.9 (%) |
| Shares Short | 2,920 (K) |
| Shares Short P.Month | 2,310 (K) |
| EPS | -0.83 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.56 |
| Profit Margin | -67.5 % |
| Operating Margin | -59.6 % |
| Return on Assets (ttm) | -28.3 % |
| Return on Equity (ttm) | -103.2 % |
| Qtrly Rev. Growth | 9.1 % |
| Gross Profit (p.s.) | 0.7 |
| Sales Per Share | 1.15 |
| EBITDA (p.s.) | -0.74 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -13 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -17.66 |
| PEG Ratio | 0 |
| Price to Book value | 26.16 |
| Price to Sales | 12.69 |
| Price to Cash Flow | -33.3 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|